Get the Stockscreener App
1.40
2.78%
-0.04
After Hours:
1.48
0.08
+5.71%
VolitionRX Ltd stock is traded at $1.40, with a volume of 550.17K.
It is down -2.78% in the last 24 hours and down -30.00% over the past month.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
See More
Previous Close:
$1.44
Open:
$1.44
24h Volume:
550.17K
Relative Volume:
0.85
Market Cap:
$16.22M
Revenue:
$2.47M
Net Income/Loss:
$-24.73M
P/E Ratio:
-0.3323
EPS:
-4.213
Net Cash Flow:
$-20.36M
1W Performance:
+2.94%
1M Performance:
-30.00%
6M Performance:
-71.09%
1Y Performance:
-90.21%
1-Day Range:
$1.40
$1.56
1-Week Range:
$1.32
$1.56
52-Week Range:
$1.30
$18.80
VolitionRX Ltd Stock (VNRX) Company Profile
Name
VolitionRX Ltd
Sector
Industry
Phone
646 650 1351
Address
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
1.40 | 16.69M | 2.47M | -24.73M | -20.36M | -4.213 |
TMO
Thermo Fisher Scientific Inc
|
472.63 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
181.35 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
573.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
128.34 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
360.54 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | H.C. Wainwright | Buy |
| Feb-01-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-17-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-10-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-18 | Initiated | Maxim Group | Buy |
| May-14-18 | Reiterated | The Benchmark Company | Buy |
| Sep-07-16 | Reiterated | Rodman & Renshaw | Buy |
| Feb-01-16 | Initiated | Rodman & Renshaw | Buy |
View All
VolitionRX Ltd Stock (VNRX) Latest News
VolitionRx Enters Securities Purchase Agreement With Investors to Raise Capital - TradingView
VolitionRx (NYSE: VNRX) prices $4.6M stock offering with $2.3M warrant upside - Stock Titan
VolitionRx (NYSE: VNRX) to Offer 2.96M Shares and 1.48M Warrants - Stock Titan
VolitionRx stock tumbles on $4.6M offering priced at discount By Investing.com - Investing.com Nigeria
VolitionRx prices $4.6 million public offering at $1.55 per share By Investing.com - Investing.com Australia
VolitionRx prices $4.6 million public offering at $1.55 per share - Investing.com
VolitionRx Announces Pricing of $4.6 Million Public Offering - marketscreener.com
Epigenetics firm VolitionRx prices $4.6M deal with $2.3M in potential warrant proceeds - Stock Titan
VolitionRx (VNRX) files shelf prospectus for stock, detachable warrants - Stock Titan
H.C. Wainwright cuts VolitionRX stock price target to $1 on share count - Investing.com
New Ebola triage blood test: VolitionRx seeks partners for outbreak zones - Stock Titan
VolitionRx Files Patent for Nu.Q NETs Test in Ebola Triage and Monitoring - Moomoo
VolitionRx (NYSE: VNRX) seeks approval to cut authorized shares and add 2026 stock plan - Stock Titan
Benchmark reiterates Hold on VolitionRX stock amid milestones By Investing.com - Investing.com South Africa
Benchmark reiterates Hold on VolitionRX stock amid milestones - Investing.com
VolitionRx Ltd stock (US92852X1037): shares trade quietly after May earnings update - AD HOC NEWS
VolitionRX (VNRX) Insider Trading Activity 2026 - MarketBeat
VolitionRx : Short Corporate Deck, May 2026 - marketscreener.com
VNRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VolitionRx reports 300% Q1 revenue growth, nears vet milestone By Investing.com - Investing.com South Africa
VolitionRx reports 300% Q1 revenue growth, nears vet milestone - Investing.com
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets - Moomoo
VolitionRX Limited (VNRX) Slides 6% as Stock Tests Key Support LevelsParabolic SAR - newsline.com
VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts - Yahoo Finance UK
VolitionRx Limited Files Form 8-K With SEC Detailing Company Information and NYSE Listing - Minichart
VolitionRx receives waiver on market capitalization covenant from Lind Global - Investing.com
VolitionRx Obtains Covenant Waiver on $9.9 Million Convertible Notes From Lind, Avoiding Acceleration - TradingView
Covenant breach leads VolitionRx (NYSE: VNRX) to secure Lind waiver and note changes - Stock Titan
VolitionRX Earnings Call: Breakthrough Science, Cash Burn Risk - TipRanks
VolitionRX Earnings Call Balances Breakthroughs and Risks - TipRanks
VolitionRx Limited (AMEX:VNRX) Q1 2026 Earnings Call Transcript - Insider Monkey
VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Partnerships Propel Growth - GuruFocus
VolitionRx director Mickie Henshall to step down, board size to be reduced - Investing.com Australia
VolitionRx director Mickie Henshall to step down, board size to be reduced By Investing.com - Investing.com South Africa
Mickie Henshall to Leave Volition Board; Company to Reduce Board Size - TradingView
VolitionRx (VNRX) director exits at 2026 meeting as board shrinks to seven - Stock Titan
Lagoda holds 17.07M VolitionRX shares after amendment (VNRX) - Stock Titan
Earnings call transcript: VolitionRx Q1 2026 sees revenue surge, EPS miss - Investing.com
Full Transcript: VolitionRX Q1 2026 Earnings Call - Benzinga
Q1 2026 VolitionRX Ltd Earnings Call Transcript - GuruFocus
Is VolitionRX (VNRX) a Value Trap After Q1 2026? EPS Not Disclos - GuruFocus
VolitionRX: Q1 Earnings Snapshot - marketscreener.com
VolitionRx Ltd stock (US92852X1037): Q1 2026 update and epigenetics business profile - AD HOC NEWS
Rising revenue but cash risk at VolitionRx (NYSE: VNRX) in Q1 2026 - Stock Titan
VolitionRx (NYSE: VNRX) lifts Q1 2026 revenue and secures new funding - Stock Titan
Cat cancer blood test may unlock $5M payout for VolitionRx - Stock Titan
VolitionRX Ltd Stock (VNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
VolitionRX Ltd Stock (VNRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reynolds Cameron John | President and CEO |
Oct 14 '25 |
Buy |
0.51 |
110,000 |
56,100 |
2,534,847 |
| Innes Guy Archibald | Director |
Oct 14 '25 |
Buy |
0.51 |
96,153 |
49,038 |
1,062,967 |
| STILL TIMOTHY I | Director |
Oct 14 '25 |
Buy |
0.51 |
48,076 |
24,519 |
1,535,458 |
| Reynolds Cameron John | President and CEO |
Sep 12 '25 |
Buy |
0.66 |
15,000 |
9,885 |
2,624,847 |
| Innes Guy Archibald | Director |
Aug 05 '25 |
Buy |
0.64 |
78,125 |
50,000 |
966,814 |
| Reynolds Cameron John | President and CEO |
Aug 05 '25 |
Buy |
0.64 |
78,125 |
50,000 |
2,609,847 |
0.56%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):